Virtual pharma API firm HRV preparing for IPO, DRHP likely in H1 of 2027: Sources
A ipo & listings development with market-wide reach.
26 Sept 2026 · Economic Times Markets
HRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs 1,000 crore revenue in…
Key facts
- Period
- FY28
The analysis
Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- This is a market-wide development — its reach goes beyond any single stock.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Jio IPO likely by Oct end at enterprise valuation of above ₹12 trillion
Jio IPO GMP latest price today: Grey market premium is rising day by day - Check expected price band
Wizz Financial bets on India with cross-border fintech push, eyes 2029 IPO
Reliance Jio IPO: Rs 37,700 crore mega issue, full schedule & 5 must-know details
Kanohar Electricals soars 20%; stock up 79% from IPO price in three weeks